Methods and compositions for production of fallopian tube epithelium

US11414648B2 · kind B2 · utility

Assignee

• Cedars Sinai Medical Center · US

Inventors

• Clive Svendsen · Santa Monica, US
• Beth Y. Karlan · Los Angeles, US
• Nur Yucer · Los Angeles, US
• Marie Holzapfel · Los Angeles, US
• Tilly Jenkins Vogel · Los Angeles, US

Key dates

• Filing date: Mar 23, 2018
• Grant date: Aug 16, 2022
• Expiry date: Mar 2, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2513/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The fallopian tube epithelium (FTE) has been recognized as a site of origin of high-grade serous ovarian cancer (HGSC). However, absence of relevant in vitro human models that can recapitulate tissue-specific architecture has hindered understanding of FTE transformation and initiation of HGSC. Here, induced pluripotent stem cells (iPSCs) were used to establish a novel 3-dimensional (3D) human FTE organoid in vitro model containing the relevant cell types of the human fallopian tube as well as a luminal architecture that closely reflects the organization of fallopian tissues in vivo. Modulation of Wnt and nodal/activin signaling pathways provided iPSC differentiation into Müllerian cells and subsequent use of pro-Müllerian growth factors promoted FTE precursors. The expression of Müllerian markers verified correct cellular differentiation. An innovative 3D growth platform, which enabled the FTE organoid to self-organize into a convoluted luminal structure, permitted final differentiation to a FTE lineage. This powerful human-derived FTE organoid model can be used to study the earliest stages of HGSC development and to identify novel and specific biomarkers of early fallopian tube ep…